Abstract

Objective: to estimate the association between preoperative hemoglobin A1c (HbA1c) levels below and above 7%, and the rate of all-cause mortality (ACM) in diabetes mellitus (DM) patients after coronary artery bypass grafting (CABG) within a ten-year follow-up period. Methods: we collected data on patient HbA1c levels that were measured up to 3 months prior to isolated CABG in consecutive patients with DM, and analyzed the rates of ACM over a median of a 5.9-year post-operative period. Results: preoperative HbA1c levels were collected in 579 DM patients. The mean HbA1c was 8.0 ± 1.7%, where 206 (35.6%) patients had an HbA1c ≤ 7% and 373 (64.4%) had an HbA1c > 7%. During the follow-up period, mortality rates were 20.4% and 28.7% in the HbA1c ≤ 7% and HbA1c > 7% groups, respectively (Kaplan-Meier estimates, log-rank p = 0.01). Multivariable Cox proportional hazards regression, adjusted for age, gender, smoking status, chronic obstructive pulmonary disease, hypertension, chronic renal failure, old myocardial infarction, number of coronary artery bypass surgeries, and post-operative glycemic control, showed a hazard ratio of 2.67 for long-term ACM (p = 0.001) in patients with HbA1c > 7%. Conclusions: DM patients with high HbA1c levels prior to CABG are at higher risk for long-term complications, especially late ACM.

Highlights

  • The prevalence of diabetes mellitus (DM) among patients who undergo coronary artery bypass grafting (CABG) has been estimated to be 14–37% [1,2,3], and continues to rise alongside the increasing prevalence of DM in the general population.The American Heart Association (AHA) and the European Society of Cardiology (ESC)recommend a target of glycated hemoglobin (HbA1c)

  • This study aims to determine whether preoperative HbA1c values can predict longterm mortality in patients with diabetes undergoing coronary bypass surgery

  • All 579 DM patients enrolled in the study had their HbA1c values measured within three months prior to undergoing CABG

Read more

Summary

Introduction

The prevalence of diabetes mellitus (DM) among patients who undergo coronary artery bypass grafting (CABG) has been estimated to be 14–37% [1,2,3], and continues to rise alongside the increasing prevalence of DM in the general population.The American Heart Association (AHA) and the European Society of Cardiology (ESC)recommend a target of glycated hemoglobin (HbA1c)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.